

Financial Results of the 1st Quarter for Fiscal Year Ending June 2026

November 14, 2025



(Securities code: 7747 Prime of Tokyo Stock Exchange,
Premier of Nagoya Stock Exchange)

*Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from this translation.*

FYE June 2026 Q1 Main Points - 1

Revenue 36,058 Mil.Yen <Year-on-year +15.6%>
Progressed favorably both Medical and Device Division
due to expanding demand, etc.

- **Medical Division ~Strong performance in both Cardiovascular and Non-cardiovascular~**
 - Cardiovascular field: Increased mainly in PCI GW in overseas regions
Europe performed well due to accelerated orders from distributors, but even excluding this impact, overall performance was strong
 - Non-Cardiovascular field: Increased in Peripheral, Abdominal Neurovascular and Gastrointestinal fields excluding China
 - OEM business: Increased in contract development transactions in the U.S.
- **Device Division ~ Increased in both Medical and Industrial Components ~**
 - Increased both Medical and Industrial Components due to the consolidation of Nitta Mold as a subsidiary
 - Medical Components business: Increased in transactions of cardiovascular inspection catheter components for the U.S.
 - Industrial Components business: Increased in overseas leisure-related transactions

- **Impact of exchange rate fluctuation**
(Yen depreciation) on Net sales was minor +53 Mil. Yen

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2026 Q1	147.45	172.28	20.60	4.56
FYE June 2025 Q1	149.63	164.22	20.84	4.29

FYE June 2026 Q1 Main Points - 2

Operating profit 13,035 Mil. Yen <YoY +34.0%>

Operating profit increased significantly due to higher sales and the improvement in gross profit margin that exceeded expectations

- **Gross profit: 25,436 Mil.Yen < YoY +18.1% >**
 - Increased due to higher sales and an improvement in gross profit margin (69.0% → 70.5%) driven by productivity improvement
 - The impact of U.S. tariffs was minimal (215 Mil. Yen) due to countermeasures in safety stock at the U.S. subsidiary.
- **Operating profit: 13,035 Mil.Yen <YoY +34.0% >**
 - SGA expenses were overall restrained (YoY +597 Mil. Yen, increase rate +5.1%)
 - Increased in sales-related expenses due to strengthen promotional activities mainly in the U.S.
 - Increased in R&D expenses (2,967 Mil.Yen) (YoY +207 Mil.Yen, R&D-to-Net sales ratio 8.2 %)
 - Decreased in goodwill amortization, etc. (YoY -388 Mil. Yen)
- **Ordinary income: 12,887 Mil.Yen <YoY +47.0% >**
 - Non-operating expenses: Decreased in foreign exchange losses (YoY -742 Mil.Yen)
- **Net income attributable to parent company shareholders: 9,205 Mil.Yen <YoY +35.7% >**
 - Extraordinary income: Decreased in allowance for doubtful accounts reversal (YoY - 100 Mil.Yen)

Highlights Year-on-Year

	FYE June 2025 Q1 Results		FYE June 2026 Q1 Results				(Reference) At the same exchange rate as the previous year			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	YoY		Amount (Mil.Yen)	Ratio (%)	YoY	
					Changes (Mil.Yen)	Changes (%)			Changes (Mil.Yen)	Changes (%)
Net sales	31,184	100.0	36,058	100.0	+4,874	+15.6	36,004	100.0	+4,820	+15.5
Gross Profit	21,529	69.0	25,436	70.5	+3,906	+18.1	25,577	71.0 [*]	+4,047	+18.8
Operating profit	9,726	31.2	13,035	36.2	+3,309	+34.0	13,216	36.7	+3,489	+35.9
Ordinary Income	8,767	28.1	12,887	35.7	+4,119	+47.0				
Net income attributable to parent company shareholders	6,784	21.8	9,205	25.5	+2,420	+35.7				
EPS (yen)	24.98	—	34.37	—	+9.39	+37.6				

*: Gross profit margin after adjusting for forex impacts other than those related to unrealized profit

Exchange rate (Unit : JPY)	US \$	EURO	CNY	BAHT
FYE June 2026 Q1	147.45	172.28	20.60	4.56
FYE June 2025 Q1	149.63	164.22	20.84	4.29

Net sales by Segment Year-on-year


	FYE June 2025 Q1 Results		FYE June 2026 Q1 Results			
	Amount (Mil.Yen)	Ratio (%)	Amount (Mil.Yen)	Ratio (%)	Changes (Mil.Yen)	Changes (%)
Medical	28,205	90.4	31,669	87.8	+3,463	+12.3
Device	2,978	9.6	4,389	12.2	+1,410	+47.4
Total amount	31,184	100.0	36,058	100.0	+4,874	+15.6

(Reference)


Medical Field	30,146	96.7	34,454	95.6	+4,307	+14.3
Device Field	1,037	3.3	1,603	4.4	+566	+54.6

Earnings Performance by Segment

Net sales




Operating profit




Attribution Analysis of Operating profit – 1

(Exchange Rate Fluctuations Included)




Attribution Analysis of Operating profit – 2

(Exchange Rate Fluctuations Excluded)



Per Segment by Medical Division (by Geography-1)

(Mil. Yen)



【Net sales (YoY)】 ~ Increased in all regions, despite the influence of orders from distributors, overall remained steady~

- Japan : Increased in Non-cardiovascular field
 - Cardiovascular field : Although Penetration Catheter increased, products for inspection decreased(*), resulting in flat trend
 - Non-cardiovascular field : Strong sales of purchased products in Peripheral vascular (Penumbra)
- Overseas : Increased in all regions, excluding the impact of forward shipments from European distributors, overall trend was solid
 - US: Brand products and OEM business performed solidly
 - Cardiovascular field : Increased mainly in PCI GW/Penetration Catheter
 - Non-cardiovascular field : Increased mainly in Abdominal and Peripheral vascular
 - OEM Business: Increased in contract development transactions
 - Europe: Increased due to forward shipments from distributors and direct sales remained also steady
 - Cardiovascular field : Increased PCI GW and Penetration catheter, Q1 shipments made at distributor's request
Direct sales area remained steady, decrease in Guiding catheters (*)
 - Non-cardiovascular : Increased in Peripheral vascular and Abdominal vascular products.
 - China: Inventory replenishment (forward shipment) due to sales network changes occurred in both previous and current terms, excluding this impact, remained steady
 - Cardiovascular field : Balloon catheter decreased due to termination of transactions*, but PCI GW performed well
 - Non-cardiovascular field : Decreased in Abdominal and Neurovascular products due to quarterly balance impact from distributor transactions
 - Other: Progressed well, overall
 - Cardiovascular field : Increased in Penetration catheters and PCI GW mainly in Asia, some decrease in products for inspection(*)
 - Non-cardiovascular field : Increased in Abdominal/ Peripheral vascular products mainly in Asia

【Operating profit】 Operating profit increased in proportion to Net sales


(* Discontinuation of low-profit products)

Per Segment by Medical Division (by Geography-2)

(Mil. Yen)		FYE June 2025 Q1 Results	FYE June 2026 Q1 Results	YoY	
				Changes	Changes (%)
Exchange rate (Yen)	USD	149.63	147.45	-2.18	-1.5
	EURO	164.22	172.28	+8.06	+4.9
	CNY	20.84	20.60	-0.24	-1.2
Total Net sales		28,205	31,669	+3,463	+12.3
Japan		3,762	4,012	+250	+6.7
Overseas		24,443	27,656	+3,212	+13.1
US		5,445	6,016	+571	+10.5
Europe		5,716	7,608	+1,891	+33.1
China		9,303	9,598	+294	+3.2
Other		3,978	4,433	+455	+11.4
Operating profit		10,190	12,504	+2,314	+22.7

Per Segment by Medical Division (by Treatment-1)


【Net sales (YoY)】



Per Segment by Medical Division (by Treatment-2)

(Mil. Yen)		FYE June 2025 Q1 Results	FYE June 2026 Q1 Results	YoY	
				Changes	Changes(%)
Exchange rate (Yen)	USD	149.63	147.45	-2.18	-1.5
	EURO	164.22	172.28	+8.06	+4.9
	CNY	20.84	20.60	-0.24	-1.2
Total Net sales		28,205	31,669	+3,463	+12.3
	Japan	3,762	4,012	+250	+6.7
	Overseas	24,443	27,656	+3,212	+13.1
	Cardiovascular	21,546	24,245	+2,699	+12.5
	Japan	2,026	2,010	-16	-0.8
	Overseas	19,519	22,234	+2,715	+13.9
	Non-Cardiovascular	4,658	5,276	+618	+13.3
	Japan	1,319	1,538	+218	+16.6
	Overseas	3,338	3,738	+400	+12.0
	OEM	2,001	2,146	+145	+7.3
	Japan	415	463	+47	+11.6
	Overseas	1,585	1,683	+97	+6.1

Per Segment by Device Division-1



【Net sales (YoY)】

Increased in both Medical components and Industrial Components
Even excluding the consolidation of Nitta Mold as a subsidiary
(+723 Mil. Yen) , results remained strong

Medical Component

- Japan : Increased due to the consolidation of Nitta Mold as a subsidiary
- Overseas : Increased transactions of cardiovascular inspection catheter components for the U.S.

Industrial Component

- Japan : Although increased due to the consolidation of Nitta Mold as a subsidiary, transactions related to constructions decreased, resulting in flat performance
- Overseas : Increased leisure-related transactions and due to the consolidation of Nitta Mold as a subsidiary

【Operating profit】

Increased due to growth in external Net sales and intersegment transaction

Per Segment by Device Division-2

(Mil. Yen)		FYE June 2025 Q1 Results	FYE June 2026 Q1 Results	(Increase due to the consolidation of Nitta Mold as a subsidiary) A	YoY		YoY excluding the impact of A	
					Changes	Changes (%)	Changes	Changes (%)
Exchange rate (Yen)	USD	149.63	147.45	-	-2.18	-1.5	-	-
Total Net sales		2,978	4,389	723	+1,410	+47.4	+687	+23.1
	Japan	721	951	293	+229	+31.9	-63	-8.8
	Overseas	2,257	3,437	429	+1,180	+52.3	+751	+33.3
	Medical Components	1,941	2,785	218	+844	+43.5	+626	+32.3
	Japan	250	469	208	+219	+87.8	+11	+4.5
	Overseas	1,691	2,315	9	+624	+36.9	+614	+36.4
	Industrial Components	1,037	1,603	505	+566	+54.6	+61	+5.9
	Japan	471	481	84	+10	+2.2	-74	-15.8
	Overseas	565	1,122	420	+556	+98.3	+136	+24.1
	Operating profit		1,351	2,471	86	+1,119	+82.8	1,033
(Reference) Segment Net sales		3,896	4,268	-	+372	+9.5	+396	+10.2


Reference: P/L

	FYE June 2025 Q1 Results		FYE June 2026 Q1 Results			
	Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Net sales	31,184	100.0	36,058	100.0	+4,874	•Both Medical Division and Device Division performed well
Cost of sales	9,654	31.0	10,621	29.5	+967	
Gross profit	21,529	69.0	25,436	70.5	+3,906	•Increase in proportion to increasing sales and gross profit margin
SGA	11,803	37.8	12,401	34.3	+597	•Increase in expenses related to sales and R&D
Operating profit	9,726	31.2	13,035	36.2	+3,309	
Non-operating income	205	0.7	164	0.5	-41	
Non-operating expense	1,164	3.7	312	0.9	-852	•Decrease in foreign exchange losses
Ordinary income	8,767	28.1	12,887	35.7	+4,119	
Extraordinary income	123	0.4	-	0.0	-123	•Decrease in allowance for doubtful accounts reversal
Extraordinary loss	-	0.0	6	0.0	+6	
Net income attributable to parent company shareholders	6,784	21.8	9,205	25.5	+2,420	
Comprehensive income	2,560	8.2	11,795	32.7	+9,234	Fluctuation in foreign currency translation adjustment account

Reference: B/S

		FYE June 2025 Results		FYE June 2026 Q1 Results			
		Amount (Mil. Yen)	Ratio (%)	Amount (Mil. Yen)	Ratio (%)	Changes (Mil. Yen)	Main comparison factors
Assets	Current assets	103,359	53.5	93,958	50.8	-9,400	Notes and accounts receivable - trade +1,950 Cash and deposits -10,981
	Fixed assets	89,827	46.5	90,887	49.2	+1,059	Tangible fixed assets +1,045
Total assets		193,187	100.0	184,846	100.0	-8,341	
Liabilities	Current liabilities	27,856	14.4	21,032	11.4	-6,824	Provision for bonuses -1,307 Income taxes payables -1,923 Other -4,147
	Fixed liabilities	13,976	7.2	14,872	8.0	+895	Deferred tax liabilities +1,339 Long-term borrowings - 595
Total liabilities		41,833	21.7	35,905	19.4	-5,928	
Total net assets		151,354	78.3	148,941	80.6	-2,412	Retained earnings +2,697 Foreign currency translation adjustment +2,189 Treasury shares -7,703
Total liabilities & net assets		193,187	100.0	184,846	100.0	-8,341	

Reference: C/F



Caution Regarding Information Presented

All forward looking statements contained herein, including revenue forecasts, outlooks, and strategic plans, are based on the best currently available data; however, risk and uncertainty are involved in these statements.

Please note that actual results may differ greatly from plans presented here.

【 IR contact 】

Asahi Intecc Co., Ltd.
corporate strategic office

TEL 0561-56-1851

URL <https://www.asahi-intecc.co.jp/en>